Boston Scientific Corporation (BSX) has been making significant strides. Despite occasional underperformance, the company's stock has been consistently rising.
Precision Wealth Strategies LLC invested $956,000 in the company, followed by
Orion Portfolio Solutions LLC and
Advisory Services Network LLC. BSX's Q4 results of 2023 and Q1 of 2024 were successful, with revenues exceeding estimates. The company's stock reached its 52-week high, reflecting its robust performance. The firm has also embarked on key strategic moves such as its acquisition of
Axonics, Inc. and
Relievant Medsystems, Inc. Boosts from new products and buyouts, along with successful pricing of €2.0 Billion of Senior Notes, demonstrate strong market position. Furthermore, BSX has received a 'Moderate Buy' rating from brokerages and a 'Buy' recommendation from Goldman Sachs. Despite insider selling of shares, investment in the company over the last five years would have yielded an 82% gain. The company's cardiac device sales have added to its value and its promising Q4 earnings in 2023 and Q1 in 2024 earnings have bullish implications for the stock. The company continues to innovate in medical technology and has announced the NAVIGATE-PF Study of the FARAWAVE™ Nav Pulsed Field Ablation Catheter.
Boston Scientific Corp BSX News Analytics from Thu, 27 Jul 2023 07:00:00 GMT to Sun, 02 Jun 2024 08:29:50 GMT -
Rating 7
- Innovation 6
- Information 8
- Rumor -3
